PRESS RELEASE published on 01/29/2024 at 14:00, 9 months 22 days ago Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update Tharimmune, Inc. initiates Phase 1 trial for TH104, a buccal film with nalmefene for liver-related pruritogenic inflammatory conditions. Phase 2 planning for PBC, near-clinical pipeline and R&D day planned. Company fully funded into 2025 Tharimmune Inc. TH104 Phase 1 Trial Buccal Film Chronic Pruritus
PRESS RELEASE published on 12/11/2023 at 14:01, 11 months 9 days ago Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
PRESS RELEASE published on 11/27/2023 at 14:00, 11 months 23 days ago Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)
Published on 11/21/2024 at 13:00, 16 minutes ago Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 16 minutes ago Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 16 minutes ago Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 16 minutes ago Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 16 minutes ago Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension
Published on 11/21/2024 at 12:35, 40 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 1 minute ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 46 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 18 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 18 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 18 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 8 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 56 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
